Compare ALLO & GCGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | GCGR |
|---|---|---|
| Founded | 2017 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 467.9M |
| IPO Year | 2018 | 2026 |
| Metric | ALLO | GCGR |
|---|---|---|
| Price | $1.25 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 107.8K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $255.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $9.96 |
| 52 Week High | $4.46 | $10.20 |
| Indicator | ALLO | GCGR |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 33.79 |
| Support Level | $1.22 | N/A |
| Resistance Level | $2.22 | $10.19 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 18.75 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.